Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen

Clinical Infectious Diseases

Volumn 45, Issue 8, 2007, Pages 1085-1092

  Gandhi, Tejal ^a   Nagappan, Vijayalakshmi ^a,d   Cinti, Sandro ^c   Wei, Wei ^b,e   Kazanjian, Powel ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^c VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^d ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

^e AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ANALYTIC METHOD; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SENSITIVITY ANALYSIS; VIROLOGY; ANTIBIOTIC RESISTANCE; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; MIDDLE AGED; MISSENSE MUTATION; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 34848915090     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/521937     Document Type: Article

References (39)

1. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-85.
2. Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC 114/ritonavir in treatment experienced HIV patients: 24-week results of POWER 1. AIDS 2007; 21:395-402.
3. Lalezari J, Goodrich J, DeJesus E, et al. Efficacy and safety of Maraviroc plus optimized background regimen in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24 week results of a phase 2b/3 study in the US and Canada [abstract 104bLB]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles). Alexandria, VA: Foundation for Retrovirology and Human Health, 2007.
4. Cooper D, Gatell J, Rockstroh J, et al. Results of BENCHMARK-1, a phase III study evaluating the efficacy and safety of MK-0518 a novel HIV-1 integrase inhibitor, in patients with triple class resistant virus [abstract 105aLB]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles). Alexandria, VA: Foundation for Retrovirology and Human Health, 2007.
5. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavirritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment -experienced HIV-1 infected patients at 48 weeks in Randomized Evaluation of Strategic Intervention in multi-drug resistant patients with Tipranavir (RESIST) studies: an analysis of combine data from two randomised trials. Lancet 2006; 368:466-75.
6. Lawrence J, Mayers DL, Huppler Hullsiek K, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003; 349:837-46.
7. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344:472-80.
8. + count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-96.
9. + T cell response after virologic failure on protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000; 181:946-53.
10. Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS 2002; 16:201-7.
11. + cell counts during antiretroviral therapy. Clin Infect Dis 2004; 39:1500-6.
12. Barbour JD, Wrin T, Grant RM, et al. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J Virol 2002; 76:11104-12.
13. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virologic failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999; 353:863-8.
14. Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L, Lamarre D. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol 1997; 71:1089-96.
15. + T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based regimens. J Infect Dis 2002; 185:315-23.
16. Gandhi T, Wei W, Amin K, Kazanjian P. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy. Clin Infect Dis 2006; 42:878-84.
17. Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T20) monotherapy. Antimicrob Agents Chemother 2002; 46:1896-905.
18. Baxter JD, Schapiro JM, Boucher CA, et al. Genotypic changes in human immunodeficiency virus-1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol 2006; 80:10794-801.
19. De Meyer S, Vangeneugden T, Lefebvre E, et al. Phenotypic and genotypic determinants of resistance to TMC 114: pooled analysis of POWER 1,2, and 3. Antivir Ther 2006; 11:S83.
20. Kantor R, Shafer RW, Follansbee S, et al. Evolution of resistance to drugs in HIV-1 infected patients failing antiretroviral therapy. AIDS 2004; 18:1503-11.
21. Kaufman D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1 infected individuals remaining viremic with highly active antiretroviral therapy (HAART). Lancet 1998; 351:723-24.
22. Nasta P, Matti A, Cocca G, et al. Early versus deferred HAART switch in heavily pre-treated HIV patients with low viral load level and stable CD4 cell count [abstract 523]. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections (Denver). Alexandria, VA: Foundation for Retrovirology and Human Health, 2006.
23. Kristiansen TB, Pedersen AG, Eugen-Olsen J, Katzenstein TL, Lundgren JD. Genetic evolution of HIV in patients remaining on a stable HAART regimen despite insufficient viral suppression. Scand J Infect Dis 2005; 37:890-901.
24. Deeks SG, Hoh R, Neilands TB, et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis 2005; 192:1537-44.
25. Katlama C, Dominquez S, Gourlain K, et al. Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS 2004; 18:217-26.
26. Castagna A, Danise A, Menzo S, et al. Lamivudine monotherapy in HIV-1-infected patients harboring a lamivudine resistant virus: a randomized pilot study (E-184V study). AIDS 2006; 20:795-803.
27. Fox Z, Dragsted UB, Gerstoft J, et al. A randomized trial to evaluate continuation versus discontinuation of lamivudine-containing regimen: the COLATE trial. Antivir Ther 2006; 11:761-70.
28. Campbell TB, Shulman NS, Johnson SC, et al. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis 2005; 41:236-42.
29. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41(RR-17):1-19.
30. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2006. Available at: http://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MemoItempGuideline& SearchpOff&GuidelineIDp7&ClassIDp1.
31. DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using standardized data analysis plan. Antivir Ther 2000; 5:41-8.
32. Gallant JE. Antiretroviral drug resistance and resistance testing. Top HIV Med 2005; 13:138-42.
33. Mosley M, Smith-Burchnell C, Mori J, et al. Resistance to the CCR5 antagonist Maraviroc is characterized by dose-response curves that display a reduction in maximal inhibition [abstract 598]. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections (Denver). Alexandria, VA: Foundation for Retrovirology and Human Health, 2006.
34. Lataillade M, Chiarella J, Kozal MJ. Natural polymorphisms of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 2006; 11:S28.
35. Olsen CH, Gatel J, Ledergerber B, et al. Risk of AIDS and death at given HIV-RNA and CD4 cell counts, in relation to specific antiretroviral drugs in the regimen. AIDS 2005; 19:319-30.
36. Raffanti SP, Fusco JS, Sherrill BH, et al. Effect of persistent moderate viremia on disease progression during HIV therapy. J Acquir Immune Defic Syndr 2004; 37:1147-54.
37. Riddler S, Jiang H, Deeks SG, et al. A5115 - a randomized pilot trial of antiretroviral switch at lower versus higher switch thresholds in subjects with virologic relapse on ART [abstract 522]. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infection (Denver). Alexandria, VA: Foundation for Retrovirology and Human Health, 2006.
38. Whitcomb JM, Parkin NT, Chappey C, Hellman NS, Petropoulos CJ. Broad nucleoside reverse transcriptase inhibitor cross-resistance in human immunodeficiency virus type I clinical isolates. J Infect Dis 2003; 188:992-1000.
39. Miller V, Phillips A, Rottmann C, et al. Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure. J Infect Dis 1998; 177:1521-32.